Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03837496 · ClinicalTrials.gov registry record · NA

Small-group, Virtual Program for Improving Symptoms and Distress Related to Hormonal Therapy for Breast Cancer Survivors

A NA study, sponsored by Massachusetts General Hospital.

Completed
Registry status
NA
Development phase
100
Enrollment target

NCT03837496: Completed NA study, sponsored by Massachusetts General Hospital.

NCT03837496 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03837496, a NA study, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
NA
Development phase
100 participants
Enrollment target

Study Summary

The purpose of this study is to explore the feasibility and acceptability of a brief, virtual, group-based cognitive-behavioral intervention for breast cancer survivors taking hormonal therapy. The intervention (STRIDE) aims to alleviate symptoms related to hormonal therapy or breast cancer, optimize medication-taking (i.e., adherence), and reduce distress.

Interventions

  • OTHER STRIDE
  • OTHER Medication Monitoring Control

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2019-10-28
Est. Completion 2021-12-01
Phase NA

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT03837496

The ClinicalTrials.gov registry entry for NCT03837496 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which STRIDE is the first listed.

NCT03837496 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03837496 about?

NCT03837496 is a clinical study titled "Small-group, Virtual Program for Improving Symptoms and Distress Related to Hormonal Therapy for Breast Cancer Survivors". The purpose of this study is to explore the feasibility and acceptability of a brief, virtual, group-based cognitive-behavioral intervention for breast cancer survivors taking hormonal therapy. The intervention (STRIDE) aims to alleviate symptoms related to hormonal therapy or breast cancer, optimiz...

What is the current status of trial NCT03837496?

This trial is currently completed. It is a NA study. The enrollment target is 100 participants. The study started on 2019-10-28. Estimated completion is 2021-12-01.

What interventions are being tested in trial NCT03837496?

The interventions under investigation include: STRIDE (OTHER), Medication Monitoring Control (OTHER).

Who is sponsoring clinical trial NCT03837496?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.